Volume 18, Number 8—August 2012
Dispatch
Vertical Transmission of Babesia microti, United States
Table
Clinical data | Reference |
||||
---|---|---|---|---|---|
(7) | (8) | (9) | (10) | This study | |
Year of diagnosis/ location | Not given/Long Island, New York | Not given/Long Island, New York | Not given/New Jersey | Not given/Long Island, New York | 2002/Westchester County, New York |
Infant age at time of symptom onset, d | 30 | 32 | 19 | 27 | 41 |
Clinical findings | Fever, irritability, pallor, hepatosplenomegaly | Fever, lethargy, poor feeding, pallor, scleral icterus, hepatomegaly | Fever, poor feeding, gagging, irritability, pallor, scleral icterus, hepato-splenomegaly | Fever, pallor | Fever, decreased oral intake, irritability, scleral icterus, pallor, hepatosplenomegaly |
Initial babesia parasitemia level, % | 5 | 4.4 | 15 | 2 | 4 |
Hospitalization, d | 6 | 5 | 8 | NA | 5 |
Maternal tick bite | 1 wk before delivery | 7 wk before delivery | 4 wk before delivery | None known | None known |
Babesia spp. serologic and PCR results for infant | 30 d after birth: IgM+/IgG+ (128/128) by IFA; 32 d after birth: IgM+/IgG+ (256/512) by IFA; PCR ND | At illness onset: IgG IFA 160; IgM/IgG immunoblot +; PCR ND | At illness onset: IgM+/IgG+ (40/256) by IFA; PCR ND | NA | Newborn screening (heel stick): IgM– (<16); total antibody + (>128) by IFA; PCR–; 6 wks after birth: IgM– (<16); total antibody + (>256) by IFA; PCR+ |
Babesia spp. evaluation results for mother | 30 d after birth: IgM+/IgG+ (2,048/1,024); 32 d after birth: IgM+/ IgG+ (4,096/1,024); peripheral smear – at time of delivery and at 30 and 32 d after birth | 7 wk before birth: IgG IFA <40; IgM/IgG immunoblot –; 2 mo after birth: IgG IFA 640; IgM/IgG immunoblot +; peripheral smear – at delivery and at infant illness onset | At infant illness onset: IgM+/IgG+ (80/>1,024) by IFA; peripheral smear negative at time of infant illness onset | At infant illness onset: PCR+ | Birth: placenta PCR+; 6 wk after birth: IgM ND; total antibody + (>256) by IFA; PCR–; peripheral smear – |
HGB, g/dL | 9.3 | 10.8 | 8.8 | NA; HCT 24.3% | 7.1 |
Platelets, x 103/μL | 38 | 87 | 34 | 101 | 100 |
Leukocytes/PMN leukocytes, cells/μL | 6,500/1,170 | NA | 9,000/1,890 | NA | 19,700/788 |
LDH, U/L | 894 | NA | 2535 | NA | NA |
Bilirubin indirect, mg/dL | 3.6 | 9.7 | 5.9 | NA | 1.6 |
AST, U/L | 90 | NA | 53 | NA | 66 |
ALT, U/L | 90 | NA | 18 | NA | 50 |
Treatment | CLI and quinine for 10 d | CLI and quinine with AZT added on day 3; on day 5 changed to AZT plus quinine for additional 7 d | AZT and ATO for 10 d | AZT and ATO, duration not given | AZT and ATO for 9 d |
Follow-up | Well at 6 mo posttreatment | Improved at 2 wk | Lost to follow-up | NA | 22 mo |
Blood transfusion for anemia | Yes, for HCT of 18% | Yes, for HGB of 7.3 g/dL | Yes, for HGB of 7.0 g/dL | Yes, for HCT of 17.3% | Yes, for HGB of 5.2 g/dL with HCT of 15.8% |
*No mothers became ill. PMN, polymorphonuclear; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase level; HCT, hematocrit; HGB, hemoglobin; IFA, indirect immunofluorescence assay. CLI, clindamycin; AZT, azithromycin; ATO, atovaquone. NA, not available; ND, not done. +, positive; –, negative.
References
- Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am. 2008;22:469–88. DOIPubMedGoogle Scholar
- de Vos AJ, Imes GD, Cullen JSC. Cerebral babesiosis in a new-born calf. Onderstepoort J Vet Res. 1976;43:75–8.PubMedGoogle Scholar
- Fukumoto S, Suzuki H, Igarashi I, Xuan X. Fatal experimental transplacental Babesia gibsoni infections in dogs. Int J Parasitol. 2005;35:1031–5. DOIPubMedGoogle Scholar
- Chisholm ES, Ruebush TK II, Sulzer AJ, Healy GR. Babesia microti infection in man: evaluation of an indirect immunofluorescent antibody test. Am J Trop Med Hyg. 1978;27:14–9.PubMedGoogle Scholar
- Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomfod JW, Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol. 1992;30:2097–103.PubMedGoogle Scholar
- Teal AE, Habura A, Ennis J, Keithly J, Madison-Antenucci S. A new real-time PCR assay for improved detection of the parasite Babesia microti. J Clin Microbiol. 2012;50:903–8. DOIPubMedGoogle Scholar
- Esernio-Jenssen D, Scimeca PG, Benach JL, Tenenbaum MJ. Transplacental/perinatal babesiosis. J Pediatr. 1987;110:570–2. DOIPubMedGoogle Scholar
- New DL, Quinn J, Qureshi MZ, Sigler S. Vertically transmitted babesiosis. J Pediatr. 1997;131:163–4. DOIPubMedGoogle Scholar
- Sethi S, Alcid D, Kesarwala H, Tolan RW Jr. Probable congenital babesiosis in infant, New Jersey, USA. Emerg Infect Dis. 2009;15:788–91. DOIPubMedGoogle Scholar
- Aderinboye O, Syed S. Congenital babesiosis in a four-week old female infant. Pediatr Infect Dis J. 2010;29:188. DOIPubMedGoogle Scholar
- Vottier G, Arsac M, Farnoux C, Mariani-Kurddjian P, Baud O, Aujard Y. Congenital malaria in neonates: two case reports and review of the literature. Acta Paediatr. 2008;97:505–8. DOIPubMedGoogle Scholar
- Malhotra I, Mungai P, Muchiri E, Kwiek JJ, Meshnick SR, King CL. Umbilical cord-blood infections with Plasmodium falciparum malaria are acquired antenatally in Kenya. J Infect Dis. 2006;194:176–83. DOIPubMedGoogle Scholar
- Lesko CR, Arguin PM, Newman RD. Congenital malaria in the United States. A review of cases from 1966 to 2005. Arch Pediatr Adolesc Med. 2007;161:1062–7. DOIPubMedGoogle Scholar
- Hagmann S, Khanna K, Niazi M, Purswani M, Robins EB. Congenital malaria, an important differential diagnosis to consider when evaluating febrile infants of immigrant mothers. Pediatr Emerg Care. 2007;23:326–9. DOIPubMedGoogle Scholar
- Joseph JT, Roy SS, Shams N, Visintainer P, Nadelman RB, Hosur S, Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis. 2011;17:843–7.PubMedGoogle Scholar
1Current affiliation: New York University School of Medicine, New York, New York, USA.
Page created: July 23, 2012
Page updated: July 23, 2012
Page reviewed: July 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.